ArteraAI is a precision-medicine company that generates prognostic and predictive insights from digitized pathology images combined with clinical data to support treatment selection and risk stratification in localized prostate cancer.
Published Jul 14, 2026
| Starting Price | Not publicly posted as a single list price; patient out-of-pocket discussed and the vendor may contact patients if out-of-pocket is expected to be high | Not posted as a simple list price; insurance/assistance programs available | Historically cited in literature/HTA discussions (figures vary by source) |
| Best For | Providers seeking an AI-on-pathology approach combined with clinical data; interest in predictive signals and relatively rapid vendor-claimed turnaround | Organizations seeking a large published validation footprint and broad evidence base | Clinicians interested in cell-cycle progression genomic risk information; usage varies by practice |
| Key Strength | Multimodal digital pathology approach; Medicare payment milestone; De Novo authorization for related software product | Extensive published validation across multiple studies and large cohorts | Established genomic test with prior HTA and outcomes discussions |
| Key Weakness | Limited independent public end-user review content; pricing opacity; adoption sensitive to scanner/lab workflows; brand name confusion with unrelated vendors | Turnaround logistics can be slower than in-lab tools; requires send-out molecular testing | Mixed views on cost-effectiveness and patient-important outcome impact in some HTA literature |
—
Where ArteraAI shows strengths
Where competitors may have advantages
Customer testimonials comparing products Direct, independently sourced clinician comparisons (for example, switching from Decipher to ArteraAI) were not prominent in the sources retrieved.
Market share / adoption trends Publicly verifiable data sufficient to quantify market share were not found outside vendor claims and partnership announcements.